Retatrutide vs Setmelanotide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: LY3437943, Triple G
A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.
Also: Imcivree, RM-493
An MC4R agonist for rare genetic obesity disorders. FDA approved for specific gene mutations causing obesity.
Key Comparison Insights
- Setmelanotide is FDA approved, while Retatrutide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Setmelanotide has stronger research evidence (FDA Approved) compared to Retatrutide (Human Trials).
Detailed Comparison
| Attribute | Retatrutide | Setmelanotide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Retatrutide activates three receptors: GLP-1 for appetite suppression and glucose control, GIP for enhanced insulin response and metabolic effects, and glucagon for increased energy expenditure and fat oxidation. The triple mechanism provides synergistic effects. | Setmelanotide activates melanocortin-4 receptors (MC4R) in the hypothalamus, restoring the satiety signaling pathway that is disrupted in certain genetic obesity syndromes. Works downstream of leptin signaling. |
| Common Dosing | 4-12 mg weekly Once weekly, same day each week | 2-3 mg daily Once daily |
| Administration | Subcutaneous injection weekly | Subcutaneous injection daily |
| Typical Duration | Long-term use expected | Long-term / chronic use |
| Best Time to Take | Morning, same day each week | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Phase 3 TRIUMPH-4 trial (Dec 2025) showed 28.7% weight loss at 68 weeks, with average loss of 71 lbs. Also showed significant osteoarthritis pain relief, reduced cardiovascular risk markers, and 14 mmHg blood pressure reduction. Seven more Phase 3 readouts expected in 2026. NDA submission expected late 2025/early 2026. First Phase 3 results (TRIUMPH-4, Dec 2025) showed 28.7% mean weight loss at 68 weeks with the 12mg dose — the highest ever reported in an obesity clinical trial (average 71.2 lbs / 32.3 kg lost). Seven more Phase 3 trials expected to report throughout 2026. | Approved for POMC, PCSK1, and LEPR deficiency obesity. Studies show significant weight loss in these specific populations where other treatments fail. Precision medicine approach. In March 2026, FDA approved an expanded indication for acquired hypothalamic obesity in adults and pediatric patients aged 4+. The Phase 3 TRANSCEND trial showed -18.4% placebo-adjusted BMI reduction. |
Frequently Asked Questions: Retatrutide vs Setmelanotide
What is the difference between Retatrutide and Setmelanotide?
Retatrutide is a weight loss peptide that a triple agonist targeting glp-1, gip, and glucagon receptors. phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. expected fda approval late 2026 to early 2027. Setmelanotide is a weight loss peptide that an mc4r agonist for rare genetic obesity disorders. fda approved for specific gene mutations causing obesity. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Retatrutide or Setmelanotide?
Neither is universally "better" - the choice depends on your specific goals. Retatrutide is typically used for weight loss purposes, while Setmelanotide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Retatrutide and Setmelanotide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Retatrutide and Setmelanotide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.